{"id":"W4409236985","doi":"10.1212/wnl.0000000000210618","title":"Tolebrutinib Versus Placebo in Non-relapsing Secondary Progressive Multiple Sclerosis: Efficacy and Safety Results from the Phase 3 HERCULES Trial (PL5.003)","year":2025,"lang":"en","type":"article","venue":"Neurology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"","keywords":"Multiple sclerosis; Placebo; Medicine; Phase (matter); Internal medicine; Oncology; Pathology; Psychiatry; Physics; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001484462,0.000727491,0.001424848,0.0002977066,0.0003624356,0.0007957171,0.0004997329,0.000989616,0.007017392],"category_scores_gemma":[0.001371632,0.0001481396,0.00118393,0.0003074176,0.0004516239,0.0007394102,0.0002585553,0.002420351,0.0008398612],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006469579,"about_ca_system_score_gemma":0.0006878935,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008191683,"about_ca_topic_score_gemma":0.002839947,"domain_scores_codex":[0.9996216,0.0002111755,0.00002258139,0.00004633277,0.00003175265,0.00006663279],"domain_scores_gemma":[0.9993462,0.0001700097,0.0001719186,0.00003338482,0.00004836865,0.0002301737],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.843085,0.006923153,0.001316668,0.00145609,0.002055035,0.0001393728,0.00009114295,0.0006119799,0.006997335,0.000367243,0.007351427,0.1296055],"study_design_scores_gemma":[0.8721089,0.111615,0.008080859,0.0002321894,0.00099777,0.0002233695,0.00006833552,0.0007433,0.001321538,0.0007024402,0.003879184,0.00002709872],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.940845,0.03779879,0.0009701066,0.003144989,0.0008415252,0.00196723,0.003842764,0.0003641218,0.01022542],"genre_scores_gemma":[0.9786096,0.008084928,0.00153859,0.002943862,0.0005617819,0.001243469,0.002641825,0.0000420704,0.004333952],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007017392,"threshold_uncertainty_score":0.02347553,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03510587589231528,"score_gpt":0.3079759663142544,"score_spread":0.2728700904219392,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}